Bispecific anti-LAG3/anti-PD-1 antibodies are currently under investigation, including in the field of advanced HCC in phase I and phase II studies (NCT04524871, NCT04140500, NCT03440437). The gene discussed is LAG3; the disease is hepatocellular carcinoma.